Shopping Cart 0
Cart Subtotal
USD 0

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 2000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 3000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the six months.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, June 2018 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, June 2018 12

2.2.1 Bayer to Raise USD20.8 Billion in Private Placement of Bonds 12

2.2.2 CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 13

2.2.3 CCRE Holdings to Acquire Remaining 94.9% Stake in China Biologic Products 13

2.2.4 Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 14

2.2.5 Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, June 2018 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, June 2018 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, June 2018 17

3.1.1 Top M&A Deals in June 2018 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, January 2018-June 2018 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, June 2018 20

3.2.1 Top Equity Offering Deals in June 2018 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, January 2018-June 2018 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, June 2018 23

3.3.1 Top PE/VC Deals in June 2018 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, June 2018 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, June 2018 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-June 2018 27

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-June 2018 28

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, June 2018 29

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, January 2018-June 2018 30

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USD m), June 2018 31

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, June 2018 32

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 33

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, January 2018-June 2018 35

3.9 harmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USD m), January 2018-June 2018 36

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), January 2018-June 2018 37

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2018 38

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2018 38

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), June 2018 39

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USD m), January 2018-June 2018 40

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USD m), January 2018-June 2018 42

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USD m), January 2018-June 2018 44

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USD m), January 2018-June 2018 46

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, June 2018 47

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, June 2018 48

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, June 2018 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, June 2018 50

5.1.1 Oncology-Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, June 2018 53

5.2.1 Central Nervous System-Deals of the Month 54

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, June 2018 56

5.3.1 Infectious Diseases-Deals of the Month 58

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, June 2018 59

5.4.1 Cardiovascular-Deal of the Month 60

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, June 2018 62

5.5.1 Immunology-Deals of the Month 63

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, June 2018 65

5.6.1 Gastrointestinal-Deal of the Month 66

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, June 2018 67

5.7.1 Metabolic Disorders-Deals of the Month 68

6 Deal Summary by Geography 70

6.1 Pharmaceuticals & Healthcare, North America Deals, June 2018 70

6.1.1 North America-Deals of the Month 71

6.2 Pharmaceuticals & Healthcare, Europe, Deals, June 2018 73

6.2.1 Europe-Deals of the Month 75

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, June 2018 76

6.3.1 Asia-Pacific-Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, June 2018 78

6.4.1 Rest of the World-Deals of the Month 79

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 80

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, January 2018-June 2018 80

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, January 2018-June 2018 81

8 Further Information 82

8.1 Methodology 82

8.2 About GlobalData 83

8.3 Contact Us 83

8.4 Disclosure information 83

8.5 Disclaimer 84


List Of Figure

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), January 2018-June 2018 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), June 2018 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), June 2018 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USD m), January 2018-June 2018 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), January 2018-June 2018 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USD m), January 2018-June 2018 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), June 2018 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), June 2018 26

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), January 2018-June 2018 27

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), January 2018-June 2018 29

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 30

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 31

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 33

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), January 2018-June 2018 37

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), January 2018-June 2018 38

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 39

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 40

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 42

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, January 2018-June 2018 44

igure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USD m), January 2018-June 2018 45

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USD m), June 2018 46

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), January 2018-June 2018 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), January 2018-June 2018 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USD m), January 2018-June 2018 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), January 2018-June 2018 59

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), January 2018-June 2018 62

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 65

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 67

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), January 2018-June 2018 70

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), January 2018-June 2018 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), January 2018-June 2018 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), January 2018-June 2018 78

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), January 2018-June 2018 80

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), January 2018-June 2018 81


List Of Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, June 2018 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), June 2018 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, June 2018 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, June 2018 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, June 2018 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, January 2018-June 2018 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), June 2018 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), January 2018-June 2018 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, January 2018-June 2018 28

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), January 2018-June 2018 29

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 30

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 31

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USD m), June 2018 32

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 34

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 36

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USD m), January 2018-June 2018 37

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 38

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 39

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 41

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USD m), June 2018 43

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 45

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), June 2018 47

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, June 2018 47

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, June 2018 48

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, June 2018 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 60

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 63

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 66

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 68

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 71

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 79

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), January 2018-June 2018 80

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), January 2018-June 2018 81

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the six months.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, June 2018 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, June 2018 12

2.2.1 Bayer to Raise USD20.8 Billion in Private Placement of Bonds 12

2.2.2 CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 13

2.2.3 CCRE Holdings to Acquire Remaining 94.9% Stake in China Biologic Products 13

2.2.4 Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 14

2.2.5 Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, June 2018 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, June 2018 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, June 2018 17

3.1.1 Top M&A Deals in June 2018 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, January 2018-June 2018 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, June 2018 20

3.2.1 Top Equity Offering Deals in June 2018 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, January 2018-June 2018 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, June 2018 23

3.3.1 Top PE/VC Deals in June 2018 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, June 2018 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, June 2018 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-June 2018 27

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-June 2018 28

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, June 2018 29

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, January 2018-June 2018 30

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USD m), June 2018 31

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, June 2018 32

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 33

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, January 2018-June 2018 35

3.9 harmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USD m), January 2018-June 2018 36

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), January 2018-June 2018 37

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2018 38

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2018 38

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), June 2018 39

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USD m), January 2018-June 2018 40

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USD m), January 2018-June 2018 42

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USD m), January 2018-June 2018 44

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USD m), January 2018-June 2018 46

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, June 2018 47

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, June 2018 48

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, June 2018 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, June 2018 50

5.1.1 Oncology-Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, June 2018 53

5.2.1 Central Nervous System-Deals of the Month 54

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, June 2018 56

5.3.1 Infectious Diseases-Deals of the Month 58

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, June 2018 59

5.4.1 Cardiovascular-Deal of the Month 60

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, June 2018 62

5.5.1 Immunology-Deals of the Month 63

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, June 2018 65

5.6.1 Gastrointestinal-Deal of the Month 66

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, June 2018 67

5.7.1 Metabolic Disorders-Deals of the Month 68

6 Deal Summary by Geography 70

6.1 Pharmaceuticals & Healthcare, North America Deals, June 2018 70

6.1.1 North America-Deals of the Month 71

6.2 Pharmaceuticals & Healthcare, Europe, Deals, June 2018 73

6.2.1 Europe-Deals of the Month 75

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, June 2018 76

6.3.1 Asia-Pacific-Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, June 2018 78

6.4.1 Rest of the World-Deals of the Month 79

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 80

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, January 2018-June 2018 80

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, January 2018-June 2018 81

8 Further Information 82

8.1 Methodology 82

8.2 About GlobalData 83

8.3 Contact Us 83

8.4 Disclosure information 83

8.5 Disclaimer 84


List Of Figure

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), January 2018-June 2018 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), June 2018 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), June 2018 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USD m), January 2018-June 2018 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), January 2018-June 2018 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USD m), January 2018-June 2018 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), June 2018 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), June 2018 26

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), January 2018-June 2018 27

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), January 2018-June 2018 29

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 30

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 31

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 33

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), January 2018-June 2018 37

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), January 2018-June 2018 38

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 39

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 40

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 42

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, January 2018-June 2018 44

igure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USD m), January 2018-June 2018 45

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USD m), June 2018 46

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), January 2018-June 2018 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), January 2018-June 2018 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USD m), January 2018-June 2018 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), January 2018-June 2018 59

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), January 2018-June 2018 62

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 65

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 67

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), January 2018-June 2018 70

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), January 2018-June 2018 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), January 2018-June 2018 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), January 2018-June 2018 78

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), January 2018-June 2018 80

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), January 2018-June 2018 81


List Of Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, June 2018 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), June 2018 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, June 2018 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, January 2018-June 2018 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, June 2018 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, June 2018 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, January 2018-June 2018 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), June 2018 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), January 2018-June 2018 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, January 2018-June 2018 28

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), January 2018-June 2018 29

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 30

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 31

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USD m), June 2018 32

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 34

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 36

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USD m), January 2018-June 2018 37

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 38

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USD m), January 2018-June 2018 39

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), January 2018-June 2018 41

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USD m), June 2018 43

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2018-June 2018 45

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), June 2018 47

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, June 2018 47

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, June 2018 48

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, June 2018 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 60

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 63

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 66

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 68

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 71

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), January 2018-June 2018 79

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), January 2018-June 2018 80

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), January 2018-June 2018 81

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials